These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29277682)

  • 1. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model.
    Alshaer W; Hillaireau H; Vergnaud J; Mura S; Deloménie C; Sauvage F; Ismail S; Fattal E
    J Control Release; 2018 Feb; 271():98-106. PubMed ID: 29277682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
    Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
    Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells.
    Alshaer W; Hillaireau H; Vergnaud J; Ismail S; Fattal E
    Bioconjug Chem; 2015 Jul; 26(7):1307-13. PubMed ID: 25343502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Versatile Nanodelivery Platform to Maximize siRNA Combination Therapy.
    Lee SK; Law B; Tung CH
    Macromol Biosci; 2017 Feb; 17(2):. PubMed ID: 27654639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of CD44s-siRNA by ScFv overcomes de novo resistance to cetuximab in triple negative breast cancer.
    Fu W; Sun H; Zhao Y; Chen M; Yang L; Yang X; Jin W
    Mol Immunol; 2018 Jul; 99():124-133. PubMed ID: 29777999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
    Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
    ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
    Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
    Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
    Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
    J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model.
    Leite Nascimento T; Hillaireau H; Vergnaud J; Rivano M; Deloménie C; Courilleau D; Arpicco S; Suk JS; Hanes J; Fattal E
    Int J Pharm; 2016 Nov; 514(1):103-111. PubMed ID: 27863652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2.
    Wullner U; Neef I; Eller A; Kleines M; Tur MK; Barth S
    Curr Cancer Drug Targets; 2008 Nov; 8(7):554-65. PubMed ID: 18991566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44 targeted delivery of siRNA by using HA-decorated nanotechnologies for KRAS silencing in cancer treatment.
    Tirella A; Kloc-Muniak K; Good L; Ridden J; Ashford M; Puri S; Tirelli N
    Int J Pharm; 2019 Apr; 561():114-123. PubMed ID: 30822503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted nanomedicine with anti-EGFR scFv for siRNA delivery into triple negative breast cancer cells.
    Nguyen PV; Hervé-Aubert K; David S; Lautram N; Passirani C; Chourpa I; Aubrey N; Allard-Vannier E
    Eur J Pharm Biopharm; 2020 Dec; 157():74-84. PubMed ID: 33059006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
    Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
    Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.
    McNamara JO; Andrechek ER; Wang Y; Viles KD; Rempel RE; Gilboa E; Sullenger BA; Giangrande PH
    Nat Biotechnol; 2006 Aug; 24(8):1005-15. PubMed ID: 16823371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RGD-based active targeting of novel polycation liposomes bearing siRNA for cancer treatment.
    Yonenaga N; Kenjo E; Asai T; Tsuruta A; Shimizu K; Dewa T; Nango M; Oku N
    J Control Release; 2012 Jun; 160(2):177-81. PubMed ID: 22019557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of tenascin С in triple-negative breast cancer].
    Popova OP; Bogomazova SY; Ivanov AA
    Arkh Patol; 2017; 79(5):10-15. PubMed ID: 29027523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.
    Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J
    J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
    Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
    Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
    Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
    Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF.
    Şalva E; Turan SÖ; Eren F; Akbuğa J
    Int J Pharm; 2015 Jan; 478(1):147-154. PubMed ID: 25445537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.